Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure.
Yan, S., Larson, G., Wu, J.Z., Appleby, T., Ding, Y., Hamatake, R., Hong, Z., Yao, N.(2007) Bioorg Med Chem Lett 17: 63-67
- PubMed: 17049849 
- DOI: https://doi.org/10.1016/j.bmcl.2006.09.095
- Primary Citation of Related Structures:  
2I1R - PubMed Abstract: 
Structure-activity relationships (SAR) of 1 against HCV NS5B polymerase were described. SAR explorations and further structure-based design led to the identifications of 2 and 3 as novel HCV NS5B inhibitors. X-ray structure of 3 in complex with NS5B polymerase was obtained at a resolution of 2.2A, and confirmed the design.
Organizational Affiliation: 
Valeant Pharmaceuticals Research and Development, 3300 Hyland Ave., Costa Mesa, CA 92626, USA. syan@valeant.com